ANGO

AngioDynamics, Inc.
$12.81
-0.26 (-1.99%)
Mkt Cap 529.30M
Volume 284,607
52W Range 8.36-13.99
Sector Healthcare
Beta 0.34
EPS (TTM) -0.75
P/E Ratio -12.29
Revenue (TTM) 313.73M
Rev Growth (5Y) +2.1%
EPS Growth (5Y) N/A
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
29.2 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 292.50M 303.91M 338.75M 316.22M 291.01M 264.16M 359.48M 344.29M 349.64M 353.69M 356.97M 354.45M
Net Income (33.99M) (184.35M) (52.44M) (26.55M) (31.55M) (166.79M) 61.34M 16.34M (7.05M) (43.59M) (3.39M) 2.35M
EPS -0.83 -4.59 -1.33 -0.68 -0.82 -4.37 1.64 0.44 0.19 -1.23 -0.09 0.09
Free Cash Flow (14.59M) (33.93M) (4.27M) (11.49M) 18.91M (22.14M) 34.32M 37.63M 52.74M 39.62M 12.95M 12.07M
FCF / Share -0.36 -0.84 -0.11 -0.29 0.49 -0.58 0.92 1.01 1.44 1.10 0.36 0.34
Operating CF (10.13M) (28.16M) 78,000 (7.19M) 24.09M (14.55M) 37.44M 41.29M 55.74M 45.22M 25.68M 24.68M
Total Assets 280.14M 317.67M 532.64M 552.75M 561.44M 595.51M 836.44M 705.47M 707.96M 728.06M 773.62M 800.16M
Total Debt 10.15M 4.73M 64.58M 33.78M 20.00M 40.84M 136.54M 93.72M 105.94M 133.46M 147.63M 153.58M
Cash & Equiv 55.89M 76.06M 44.62M 28.82M 48.16M 54.44M 227.64M 74.10M 47.54M 32.33M 18.39M 16.11M
Book Value 182.97M 205.59M 378.30M 424.49M 439.46M 455.87M 614.82M 542.60M 517.03M 507.03M 545.02M 537.89M
Return on Equity -0.19 -0.90 -0.14 -0.06 -0.07 -0.37 0.10 0.03 -0.01 -0.09 -0.01 0.00
ANGO News
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
Jun 30, 2026 04:00 AM · businesswire.com
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
Jun 23, 2026 10:11 AM · zacks.com
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
Jun 18, 2026 06:55 AM · zacks.com
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Jun 17, 2026 04:30 AM · businesswire.com
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Jun 10, 2026 08:12 AM · seekingalpha.com
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
May 28, 2026 09:25 AM · businesswire.com
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026 04:30 AM · businesswire.com
Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
May 22, 2026 06:56 AM · zacks.com
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
May 19, 2026 08:50 AM · zacks.com
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
May 13, 2026 05:00 AM · businesswire.com